Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The discovery of Hendra foreshadowed three decades of emerging infectious diseases dominated by bat-borne zoonotic viruses – ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...